The Impact of T Cell Vaccination in Alleviating and Regulating Systemic Lupus Erythematosus Manifestation

Abstract EN

Objective.

Systemic lupus erythematosus (SLE) is an autoimmune disease identified by a plethora of production of autoantibodies.

Autoreactive T cells may play an important role in the process.

Attenuated T cell vaccination (TCV) has proven to benefit some autoimmune diseases by deleting or suppressing pathogenic T cells.

However, clinical evidence for TCV in SLE is still limited.

Therefore, this self-controlled study concentrates on the clinical effects of TCV on SLE patients.

Methods.

16 patients were enrolled in the study; they accepted TCV regularly.

SLEDAI, clinical symptoms, blood parameters including complements 3 and 4 levels, ANA, and anti-ds-DNA antibodies were tested.

In addition, the side effects and drug usage were observed during the patients’ treatment and follow-up.

Results.

Remissions in clinical symptoms such as facial rash, vasculitis, and proteinuria were noted in most patients.

There are also evident reductions in SLEDAI, anti-ds-DNA antibodies, and GC dose and increases in C3 and C4 levels, with no pathogenic side effects during treatment and follow-up.

Conclusions.

T cell vaccination is helpful in alleviating and regulating systemic lupus erythematosus manifestation.